SEC Tracker
Get the app

Akebia Therapeutics AKBA

Akebia Therapeutics reported $36.9 million in revenue for Q3 2026.

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $36.9 million for the three months ended Sep 30, 2026
  2. Net loss: $14.35 million for the three months ended Sep 30, 2026
  3. Cash and equivalents: $159.25 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Akebia Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

From the filing's financial data, not stated in its text

From this 10-Q's financial data (XBRL) for the quarter ended September 30, 2026

  • For the quarter ended September 30, 2026, Akebia Therapeutics, Inc. reported: Revenue $36.9 million.
  • Net income -$14.4 million.
  • Gross margin 82.8%.
  • Operating margin -31.1%.
  • Net margin -38.9%.
  • Revenue change from a year earlier -37.2%.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Viridian Therapeutics VRDN public float $943M, Jun 30, 2025
  2. Collegium Pharmaceutical COLL public float $926M, Jun 30, 2025
  3. Ardelyx ARDX public float $924M, Jun 30, 2025
  4. Neogen NEOG public float $972M, Nov 30, 2025
  5. CorMedix CRMD public float $910M, Jun 30, 2025